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Abstract
Background: Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, also referred to as Müllerian aplasia, is a congenital
disorder characterized by aplasia of the uterus and upper part of the vagina in females with normal secondary sex
characteristics and a normal female karyotype (46,XX).
Main body: The diagnosis is often made during adolescence following investigations for primary amenorrhea and
has an estimated prevalence of 1 in 5000 live female births. MRKH syndrome is classified as type I (isolated uterovaginal
aplasia) or type II (associated with extragenital manifestations). Extragenital anomalies typically include renal, skeletal, ear,
or cardiac malformations. The etiology of MRKH syndrome still remains elusive, however increasing reports of familial
clustering point towards genetic causes and the use of various genomic techniques has allowed the identification of
promising recurrent genetic abnormalities in some patients. The psychosexual impact of having MRKH syndrome should
not be underestimated and the clinical care foremost involves thorough counselling and support in careful dialogue with
the patient. Vaginal agenesis therapy is available for mature patients following therapeutical counselling and education
with non-invasive vaginal dilations recommended as first-line therapy or by surgery. MRKH syndrome involves absolute
uterine factor infertility and until recently, the only option for the patients to achieve biological motherhood was through
gestational surrogacy, which is prohibited in most countries. However, the successful clinical trial of uterus transplantation
(UTx) by a Swedish team followed by the first live-birth in September, 2014 in Gothenburg, proofed the first available
fertility treatment in MRKH syndrome and UTx is now being performed in other countries around the world allowing
women with MRKH syndrome to carry their own child and achieve biological motherhood.
Conclusion: Several advances in research across multiple disciplines have been made in the recent years and this
kaleidoscopic review provides a current status of various key aspects in MRKH syndrome and provides perspectives for
future research and improved clinical care.
Keywords: MRKH syndrome, MRKHS, Disorders of sex development, 46,XX DSD, Female infertility, Female genitalia,
Müllerian aplasia, Vaginal agenesis, Uterus transplantation, Genetics
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Background
Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome
[ICD-10 Q51.0/Q52.0; OMIM %277000/%601076;
ORPHA 3109], also referred to as Müllerian aplasia or
congenital absence of the uterus and vagina, is a con-
genital disorder characterized by agenesis or aplasia of
the uterus and upper part of the vagina in females with
a normal female karyotype (46,XX) (Fig. 1). The external
genitalia appear normal and the patients typically have a
normal reproductive endocrine function and reach pu-
berty showing normal signs of thelarche and pubarche.
Patients typically present with primary amenorrhea dur-
ing adolescence and MRKH syndrome has been reported
in ~ 16% of patients with primary amenorrhea, thus con-
sidered the second most common cause hereof after
ovarian failure [1]. Müllerian aplasia can be associated
with extragenital malformations involving mainly the
kidneys and skeleton.
During the last decade several advances have been
made in MRKH syndrome research, especially within the
fields of genetics, non-surgical management, and uterus
transplantation as the first available fertility treatment.
Herein, we provide a detailed kaleidoscopic review of
key aspects on MRKH syndrome including the most re-
cent advances in the field.
Main text
Epidemiology
The prevalence of MRKH syndrome is generally consid-
ered to be in 1 in 5000 live female births but it remains
poorly investigated [2, 3]. The first reported prevalence
was on vaginal agenesis by John Engstad in 1917, where
he suggested a 1 in 5000 prevalence based on nine pa-
tients in his clinic [4]. Other estimates range from 1 in
4000-20,000. In 1942, Owens found six patients in 125,
000 admissions [5]. Bryan et al. in 1949 reported a
prevalence of 1 in 4000 females based on 100 patients
with vaginal agenesis [6]. Later in 1981, Evans et al. re-
ported the first population-based prevalence in the state
of Michigan being 1 in 10,588 females. It is important to
consider that perhaps not all patients in these cohorts
had MRKH syndrome as other diagnoses may also
present with vaginal agenesis. To date, only two
population-based studies investigating the prevalence of
MRKH syndrome have been published. Aittomäki et al.
reported on a cohort of 161 patients treated at the five
Fig. 1 a The original illustration by Carl von Rokitansky (1838) showing the uterovaginal morphology in MRKH syndrome with a shortened blind-
ending vagina and two rudimentary uterine remnants. b A sagittal T2-weighted MRI showing complete uterovaginal absence in type II MRKH
syndrome associated with renal agenesis and a solitary pelvic kidney. c The pelvis of a patient with MRKH syndrome during surgical preparation
for uterus transplantation. The forceps is holding the fibrous uterine rudiment in the midline, while it is dissected free from the bladder. On the
uterine buds, located on the pelvic sidewalls, small subserosal leiomyomas are seen on both sides. The ovaries are located medially towards the
Pouch of Douglas
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university hospitals in Finland from 1978 to 1993.
Seventy-seven of the patients, born from 1960 to 1969,
were included in the prevalence estimate of 1 in 4961
newborn girls [2]. Recently, Herlin et al. reported on a
cohort in Denmark identified through searches in the
National Danish Patient Registry from 1994 to 2015
followed by medical chart reviews. From the cohort of
168 patients, 138 patients born from 1974 to 1996 were
included and resulted in a prevalence of 1 in 4982 (95%
confidence interval: 4216-5887) live female births [3].
The two studies were based on European populations
and thus, it remains unknown whether the prevalence in
other populations differs.
History and classification
MRKH syndrome is named after the authors of the four
original descriptions published over a 130 year period by
German anatomist August Franz Josef Karl Mayer
(1829), Austrian anatomist Carl von Rokitansky (1838;
Fig. 1a), German gynecologist Hermann Küster (1910)
and Swiss gynecologist Georges Andre Hauser (1961)
[7–10]. The first description of congenital absence of the
uterus and vagina, however, is attributed to the Italian
anatomist Realdo Colombo although his descriptions
lacked detail. In his main work De Re Anatomica from
1562, he described in volume 15 titled De iis quae raro
in anatome reperiuntur (eng. “rare findings in anatomy”)
an entity he named vulva rara in a woman with no
womb and vagina who complained of pain upon coitus
[11]. Centuries after Mayer and Rokitansky independ-
ently reported on autopsies of two deceased women in
which they identified rudimentary uterine buds and de-
scribed what they referred to as uterus bipartitus solidus
cum vagina solida [7, 8]. Küster was the first to report
this finding in a living patient from whom he removed
the pain-causing uterine remnants [9], whereas Hauser
and Schreiner completed the definition of uterovaginal
agenesis in women with normal secondary sex character-
istics and normal female karyotype based on a series of
21 cases [10].
These contributions all described isolated uterovaginal
agenesis with no associated extragenital malformations,
which in contemporary literature is referred to as type I
MRKH syndrome. In 1977, Schmid-Tannwald and
Hauser described seven cases with renal malformations
which was named atypical MRKH syndrome [12]. Duncan
et al. reported two cases with a severe phenotype of utero-
vaginal agenesis associated with renal and skeletal malfor-
mations and suggested the entity MURCS association
(Müllerian duct aplasia, renal aplasia and cervicothoracic
somite dysplasia). In current literature these two sub-
groups are grouped together as type II MRKH syndrome
referring to all cases with any associated extragenital ab-
normality (renal, skeletal, and others). The frequency of
type I and type II MRKH syndrome is 56–72% and 28–
44%, respectively [3, 13–15].
Embryology, etiology, and genetics
The female reproductive tract in humans includes the
oviducts (Fallopian tubes), uterus, cervix and vagina. The
oviducts, uterus, cervix, and upper two-thirds of the va-
gina origin from the paramesonephric (Müllerian) ducts
(PMD), whereas the lower part of the vagina origins
from the urogenital sinus [16]. Formation of the PMD
starts around 5th–6th gestational week as bilateral cra-
niocaudal invaginations of the coelomic epithelium of
the urogenital ridges (intermediate mesoderm) growing
caudally guided by the mesonephric (Wolffian) ducts to
reach the urogenital sinus (endoderm) [17]. The caudal
part of the two PMDs fuses to form the uterus, cervix
and upper vagina, whereas the upper parts of the PMDs
form the two oviducts. MRKH syndrome is caused by
either complete agenesis or aplasia of the PMDs to form
the uterus and upper vagina.
The etiology of MRKH syndrome still remains unclear.
Tissue patterning and organ morphogenesis in the
human embryo is a complex process and result from a
combination of timely cues from genetic factors, soluble
morphogens, chemical factors and mechanical forces
[18] and several possible etiologies should therefore be
considered at this current state of knowledge including
monogenic, oligogenic, polygenic, multifactorial, and en-
vironmental factors. Moreover, regulatory mechanisms
(e.g. epigenetic factors) and somatic genetic events dur-
ing development could also be involved. Increasing re-
ports of familial occurrence of MRKH syndrome and its
associated anomalies support a monogenic genetic eti-
ology [19, 20]. Most pedigrees suggest autosomal domin-
ant inheritance with incomplete penetrance and this
especially seems to include families with aggregation of
both MRKH syndrome and renal abnormalities which in
previous literature has been referred to as hereditary
urogenital adysplasia [19, 21–24]. In contrast, most cases
occurring sporadically, lacking recurrence in outcomes
of surrogate pregnancies [25, 26] and several reports of
discordant twin pairs [3, 27–30] support either polygenic/
multifactorial or non-genetic etiologies (e.g. teratogenic
exposures in utero [31]). Discussing possible etiologies for
MRKH syndrome and the predominance of mainly spor-
adic cases, however, it should be remembered that the na-
ture of MRKH syndrome involving absolute uterine factor
infertility hinders vertical transmission of the trait and
thus, the genetic contribution in MRKH syndrome may
therefore be underestimated.
Early genetic studies used a hypothesis-based candi-
date gene approach. In male embryos, anti-Müllerian
hormone (AMH) inhibits the development of Müllerian
structures, which led to idea of overexpression of AMH
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and its receptors as a cause of MRKH syndrome. How-
ever, studies have failed to find evidence for this hypoth-
esis [32–34]. Several other candidate genes based on
developmental pathways and associated diseases have
disproved to cause MRKH syndrome [35–48]. Mutations
in WNT4 were detected in patients with Müllerian apla-
sia and virilization/hyperandrogenism [49–51]. However,
this should be considered a separate entity and not a
cause of MRKH syndrome (OMIM #158330) [52–54].
Furthermore, genetic variants have been reported in the
WNT9B gene, involved in genitourinary development
acting upstream of WNT4 [55, 56]. Recently, a study in-
vestigated male microchimerism as a possible cause but
again without finding evidence to support this [57].
Several interesting genetic findings emerged following
the advent use of chromosomal microarray. This method
enabled hypothesis-free genome-wide searches for
chromosomal imbalances (deletions/duplications) and
several recurrent copy number variations (CNV) have
been identified located at chromosomal regions 1q21.1,
16p11.2, 17q12, and 22q11.21 (summarized Table 1) [20,
44, 58–63, 65–67]. Still, it is important to be cautious
concluding these findings as confirmed pathogenic le-
sions. The most promising genetic CNVs are 17q12 and
16p11.2. The 17q12 locus encompasses LHX1 and
HNF1B. Single nucleotide variants in LHX1 have been
reported in MRKH syndrome [59, 71] and Lim1 knock-
out in mice results in a Müllerian aplasia [68]. Variants
in HNF1B have been associated with various renal and
uterine abnormalities [75, 76], however its exact role in
MRKH syndrome pathogenesis is uncertain. The
16p.11.2 locus encompasses the TBX6 gene in which sin-
gle nucleotide variants of unknown significance have
also been reported [55, 63, 69, 70].
Despite the progress following chromosomal micro-
array, genetic findings reported so far only apply to a mi-
nority of patients. During the last decade, the increasing
availability of massively parallel sequencing technologies
(also referred to as Next-Generation Sequencing, NGS)
has provided new optimism in the search for genes im-
plicated in MRKH syndrome. Recently, Pan et al. per-
formed whole-genome sequencing (WGS) analysis of
nine MRKH syndrome trios (patient and both parents)
demonstrating the capacity of WGS in unbiased detec-
tion of de novo genomic variation [77]. Other recent
studies also used NGS technology in genomic searches
for genetic variation [24, 64, 78, 79]. However, it remains
a challenge to interpret the pathogenicity of these find-
ings and investigations of larger cohorts will likely be
needed in order to identify recurrent genetic variation.
Furthermore, it is essential to obtain a detailed family
history and consider radiological examinations for subtle
genitourinary anomalies in relatives of the patients. In
2019, Herlin et al. described whole-exome sequencing
(WES) in a three-generation family with two female
cousins having type II MRKH syndrome and unilateral
renal agenesis, and two male relatives with renal agene-
sis. The study reported a co-segregating missense variant
in GREB1L (Table 1) [24], a gene identified in 2017 to
cause bilateral renal agenesis in fetuses of which several
female fetuses also had uterus agenesis [73, 74]. Just re-
cently, Jacquinet et al. reported four additional multiplex
families with either type II MRKH syndrome or uterova-
ginal aplasia (fetuses) associated with renal malforma-
tions (agenesis in particular) in which pathogenic
GREB1L variants were identified from WES data [72].
GREB1L now seems to be the first gene to show a strong
association with type II MRKH syndrome with kidney
anomalies following autosomal dominant inheritance
with incomplete penetrance.
Continuous research in the genetics of MRKH syn-
drome is imperative to provide better knowledge of the
pathogenesis and improve the patient care and counsel-
ling. However, the anticipated identification of novel
monogenic causes of MRKH syndrome brings forward
new difficult questions. The increasing availability of
uterus transplantation as fertility treatment or in vitro
fertilisation (IVF) using a gestational carrier will allow
more patients to achieve biological motherhood in the
future, and thus we could expect an increasing demand
for prenatal diagnostics including preimplantation gen-
etic testing from some patients having a genetic diagno-
sis for their disorder. Views on prenatal genetic testing
are highly individual and some patients will request it,
while others will oppose it. Therefore, the reproductive
autonomy of each patient should always be respected.
Importantly, such options should only be considered for
patients with a robust genetic diagnosis with a notable
recurrence risk and should always be preceded by thor-
ough genetic counseling.
Clinical presentation, diagnosis, and associated
malformations
Patients with MRKH syndrome typically present during
adolescence with primary amenorrhea defined as absent
menstrual periods at the age of 16 following normal pu-
berty and development of secondary sex characteristics.
Other complaints at referral include dyspareunia/apareu-
nia and (cyclic) abdominal pain. Finally, patients (typic-
ally younger children) may be referred after an
incidental finding of vaginal or uterus agenesis, but if ex-
amined by imaging at young age such findings may be
false interpretations of the prepubertal uterus. Median
age at referral has been reported to be 17.5 years (inter-
quartile range: 16–19) [3].
Table 2 summarizes the routine diagnostic work-up
and typical findings in MRKH syndrome. Patients with
primary amenorrhea should be referred to a gynecology
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department or a gynecologist with expertise in pediatric/
adolescent gynecology or disorders in sex development
(DSD) for examination. Physical examination is carried
out which may include examination of external genitalia
and examination of the introitus/vagina with respect to
the patient’s age and motivation (should be avoided in
prepubertal adolescents). Transperineal or transabdom-
inal ultrasonography (US) is performed revealing the ab-
sence of the uterus and presence of ovaries. Magnetic
resonance imaging (MRI) of the internal genitalia is con-
sidered the golden standard method for the diagnosis of
uterovaginal agenesis in MRKH syndrome and should al-
ways be performed when available. MRI is non-invasive
and superior to computed tomography (CT) in showing
the Müllerian structures in detail (uterine remnants or
complete agenesis) including the presence of endomet-
rium in uterine remnants. MRI also shows the ovaries
and extragenital malformations, and has high interrater
agreement with laparoscopy [80, 81]. Thus, laparoscopy
is rarely indicated for diagnostic purposes only, but may
be relevant in patients with pain-causing uterine rem-
nants where surgical removal of the tissue is needed
[82]. Examination of the kidneys by US/MRI should be
performed to screen for renal malformations (prevalence
of ~ 30%) [3, 81]. Detailed screening of other typical
extragenital anomalies (skeletal, ear, cardiac etc.), by im-
aging and otorhinopharyngeal assessment, is not done
routinely but should be considered in case of relevant
complaints or findings at the physical examination.
More studies are still needed to conclude on the
relevance of a full screening of extragenital abnormalities
for all patients and its recommendation in clinical prac-
tice. Chromosomal analysis by G/Q-banding is often
performed to confirm normal female karyotype (46,XX).
Chromosomal microarray analysis can be considered for
the detection of copy number variations but is not obli-
gate for the diagnosis. Overall test positive rate for im-
balances has been reported at ~ 16–20% but the
interpretation of the pathogenicity of these findings re-
mains a challenge [20, 61, 63]. Other relevant laboratory
tests include FSH, LH, androgens and estradiol, which
are generally considered to be normal in MRKH syn-
drome [3, 83]. However, biochemical (non-clinical)
hyperandrogenemia was recently reported in ~ 50% of
patients [84], but this finding requires further validation.
Uterus agenesis/aplasia in MRKH syndrome has two
phenotypic presentations. Two aplastic uterine buds on
the pelvic sidewall derived from the Müllerian ducts
(often seen in type I) or complete absence of one or both
Müllerian ducts (often seen in type II associated with ip-
silateral kidney malformations). The two uterine buds
are seen in combination with a uterine remnant or fi-
brous band in the midline (Fig. 1c). Presence of uterine
remnants have been reported in 48–95% of the patients
[85–89] and is associated with a risk of cyclic (catame-
nial) abdominal pain due to the presence of active endo-
metrium [85, 87, 90]. Some patients with endometrium
that respond to the cyclic steroid changes of the men-
strual cycle may even develop hematometra due to cryp-
tomenorrhea in the remnant cavity [91, 92]. In case of
Table 2 Routine diagnostic work-up in MRKH syndrome
Examination Typical findings
Physical examination including a precautious pelvic exam by an
experienced pediatric/adolescent gynecologist.
Normal height, secondary sex characteristics, and hair growth.
Normal external genitalia.
Short blind-ending vagina (0–3 cm) with no cervix at the apex.
No uterus detected by manual palpation.
Radiologic examination
US of internal genitalia
(transvaginal/−perineal)a
No uterus or vaginal canal.
Two functional ovaries.
Pelvic MRI scan Confirms the diagnosis.
Determines the presence of rudimentary uterine buds
or complete uterovaginal agenesis
Renal scan (by US or MRI) Renal abnormalities are found in approximately 30% of patients
Consider examinations for other associated malformations
(e.g. EOS scan, otorhinopharyngeal assessment and
echocardiography
Various skeletal malformations (axis and limbs), hearing
impairment and congenital heart defects (rare).
Biochemical analysis
Gonadotropins (FSH, LH) Normal levels following menstrual cycle
Estradiol Normal levels
Androgen status Normal female levels
Chromosomal analysis (can be used to differentiate from 46,XY DSDs) 46,XX
Abbreviations: FSH follicle stimulating hormone, LH luteinizing hormone, MRI magnetic resonance imaging, US ultrasonography
aTransabdominal US should be considered in younger patients
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cyclic abdominal pain and endometrial activity on MRI,
laparoscopy and surgical removal of the uterine remnants
containing endometrium should be considered. Endomet-
riosis is another feature which may occur in MRKH syn-
drome, especially in patients with uterine remnants and
active endometrium [85, 93]. This phenomenon in MRKH
syndrome is often hypothesized to be explained by retro-
grade menstruation (Sampson’s implantation theory)
which is further supported by the association of endomet-
riosis with other obstructive Müllerian anomalies, e.g.
Herlyn-Werner-Wunderlich syndrome [94, 95]. However,
it should be noted that the implantation theory does not
fit with all endometriotic lesions including endometriosis
in MRKH syndrome patients with no uterine remnants
and extra-abdominal endometriosis for which other theor-
ies are valid [96]. Other gynecological features that might
be encountered in MRKH syndrome include leiomyomas
in the rudimentary uterus (Fig. 1c) [97], adenomyosis [98]
and inguinal ovarian/Müllerian duct hernias [99, 100].
In MRKH syndrome, both ovaries are typically present
and well-functioning. However, their anatomical position
is usually more cranial than the normal position and they
are often found lateral, rather than medial, to the external
iliac arteries, probably due to the lack of Fallopian tube
development. Ovary anomalies are rare and only found in
~ 5–10% [3, 13, 101]. Different anomalies previously re-
ported include unilateral agenesis, ectopic ovaries, poly-
cystic ovaries, streak ovaries, and rarely tumors [102].
As mentioned above, MRKH syndrome is classified into
two groups. Type I (isolated) without any extragenital ab-
normalities and type II (including MURCS association) with
presence of extragenital abnormalities. Table 3 summarizes
the extragenital abnormalities reported from larger cohorts
[3, 14, 15, 86, 101, 103–105]. Renal malformations are the
most frequent extragenital abnormalities in MRKH syn-
drome occurring in ~ 30–40% in European cohorts. Unilat-
eral renal agenesis (URA) is the most frequent anomaly
accounting for around half of all renal malformations asso-
ciated with MRKH syndrome (Fig. 1b). Notably, URA is
often associated with complete absence of the ipsilateral
Müllerian duct which suggests a close relationship between
early kidney and Müllerian duct development [81]. Other
renal malformations include pelvic kidney, duplex kidney,
and horseshoe kidney (Table 3). Interestingly, Deng et al.
reported a lower prevalence of renal malformations of only
13% in their Chinese cohort suggesting the possibility of
inter-ethnic phenotypical variations in MRKH syndrome
from European patient cohorts [15]. Pan et al. reported an
even lower prevalence of 5% in their Chinese cohort but
that study did not include information on the extent of
renal examinations performed, which could imply an
underestimation of the prevalence [106]. Anomalies of the
skeleton are the second most frequent extragenital manifes-
tations in MRKH syndrome affecting around ~ 10–40%
depending on the extent of examinations performed and
anomalies included (Table 3). Skeletal anomalies typically
involve the axial skeleton (e.g. scoliosis, Klippel-Feil anom-
aly, hemivertebrae, rib aplasia etc.) and more rarely the ex-
tremities. Cardiac abnormalities are reported in < 5% of
patients (e.g. pulmonary valve stenosis, atrial septal defect).
Hearing impairment including both sensorineural and con-
ductive hearing loss (e.g. external meatus atresia, stapedial
ankylosis) are generally reported in < 5%, but is not rou-
tinely examined. Strübbe et al. performed a systematic
evaluation of associated anomalies with otorhinopharyngeal
assessment and reported ear abnormalities in 11% of pa-
tients, which could indicate an underestimation [107]. In a
small number of patients, MRKH syndrome has been re-
ported with a very severe phenotype: vertebral defect, anal
atresia, cardiac defect, tracheoesophageal fistula/esophageal
atresia, renal defect, and limb defect (VACTERL associ-
ation), while even fewer have been reported with isolated
anorectal malformations [3, 103, 108].
Differential diagnosis
Several other diagnoses show similarities with MRKH syn-
drome. Vaginal agenesis is occasionally misinterpreted as
imperforate hymen or transverse vaginal septum in which
US exam will reveal a proximal vaginal canal and possibly
hematocolpos. Such misinterpretations may have unfortu-
nate iatrogenic implications [109]. A rare form of Müllerian
agenesis in females is associated with clinical virilization/
hyperandrogenemia and is caused by mutations in WNT4
(OMIM #158330) and generally considered a separate en-
tity from MRKH syndrome [49]. Müllerian agenesis is
sometimes falsely reported in 46,XX and 45,X females with
ovarian insufficiency (gonadal dysgenesis) and estrogen de-
ficiency. However, in these patients exogenous exposure to
estrogen have been reported to induce uterus development
suggesting absent pubertal uterine development and not
agenesis [110]. In general, imaging of the prepubertal uterus
should be cautiously interpreted due to the risk of false
positive conclusions of agenesis/aplasia.
Several features are also shared with various 46,XY disor-
ders of sexual development. Complete androgen insensitiv-
ity syndrome (CAIS, also referred to as Morris syndrome)
which is an X-linked disorder affecting genetically males
(46,XY) caused by hemizygous mutations in the androgen
receptor gene, AR (OMIM #300068). These patients have
normal female appearance, blind-ending vagina and absent
uterus and have breast development but sparse pubic hair
at puberty. Also, 17-hydroxylase/17,20-lyase deficiency in
46,XY females caused by biallelic CYP17A1 mutations in-
clude normal (or sometimes ambiguous) external genitalia,
absent uterus and a shortened vagina due to incomplete
masculinization (OMIM #202110) [111]. In doubt of these
differential diagnoses, chromosomal analysis is useful and
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should be considered in order to differentiate MRKH syn-
drome from 46,XY DSDs.
Psychological and psychosexual issues in MRKH
syndrome
The diagnosis of MRKH syndrome may have profound
psychological and/or psychosexual impact and it is a hall-
mark in the management to counsel the patient and sup-
port mental health upon the diagnosis and onwards in life
[82, 112, 113]. Receiving the diagnosis, many patients ex-
perience facing overwhelming issues regarding identity,
sexuality and infertility, and the importance of good caring
and counselling should not be underestimated. The diag-
nosis is often made during adolescence; a period of sensi-
tive physical/emotional development and vulnerability,
which further imposes the provider’s caring and awareness
towards the patients’ emotions, reactions and coping strat-
egies. Furthermore, it is important to be aware of potential
cultural aspects and their influence on reactions to the
diagnosis in patients and their families and peers.
Knowledge of the psychological aspects in MRKH syn-
drome remains limited but studies have agreed on pres-
ence of higher levels of psychological distress in patients
compared with women without MRKH syndrome [114,
115]. Most studies have been focusing on sexual function
and well-being using quantitative survey testing such as
Female Sexual Functioning Index (FSFI) and Female Sex-
ual Distress Scale-Revised (FSDS-R), which particularly
have been used measuring functional outcome following
neovaginal therapy [116–118]. Other studies have also fo-
cused on specific psychological/psychiatric symptoms
such as self-esteem, depression and anxiety [114, 115, 119,
120]. Bargiel-Matusiewicz et al. reported increasingly
higher neuroticism following diagnosis as well as low level
of problem-focused coping style [121]. To our knowledge
only two qualitative studies on psychological issues in
MRKH syndrome have been published providing valuable
insight to the lived experience of having MRKH syndrome
[122, 123]. Ernst et al. reported on motivators and barriers
to disclosure, emotions receiving the diagnosis and its im-
pact onwards in life [122]. Patterson et al. identified four
major themes having MRKH syndrome: hindered inde-
pendence in relation to the mother’s involvement in the
care, feelings of being different, difficulties managing in-
timacy, and the threat to female identity [123].
Sexuality and sexual activity are complex concepts
which should be viewed in the broadest senses and not
merely limited to the mechanistic ability to engage pene-
trative intercourse [124]. The World Health Organization
(WHO) suggests a holistic approach describing sexuality
in biopsychosocial terms. In this view, it is important to
recognize the patient’s possibilities and abilities to reach
good self-esteem and well-being, establish sexual relations,
and empower the patient with coping capabilities to
navigate through the psychosexual challenges which may
follow having MRKH syndrome [115]. While recognizing
the challenge for any health-care professional to provide
sufficient counselling and support, referral to experts in
genital malformations and/or disorders of sexual develop-
ment, sexologists or psychologists is often relevant and
should always be considered.
Many patients experience difficulties talking about
feelings and emotions related to MRKH syndrome.
Therefore, patients should be encouraged to gain trust
with someone close (parents, partner, friend) with whom
thoughts can be shared [122]. Sharing thoughts and
emotions with other patients can be valuable and group
programs for women with MRKH syndrome have been
reported to decrease psychological distress [125, 126].
Patients should also be encouraged to connect to a peer
support group allowing them to learn from other pa-
tients’ experiences. There are several support groups
established worldwide (see list at ref. [127]).
Management of vaginal agenesis
Historically, correction of vaginal agenesis in MRKH syn-
drome with creation of a functional neovagina has been a
hallmark in the treatment. During the last hundred years,
various different surgical and non-surgical methods have
been suggested for vaginal construction. Surgical procedures
include vaginoplasties using various autografts such as
McIndoe vaginoplasty (split-skin graft covering a mold
placed in the dissected pouch between the rectum and blad-
der), Baldwin vaginoplasty (bowel graft), Davydov vagino-
plasty (peritoneal graft), and Williams vulvavaginoplasty
(labia majora flaps) [128–131]. More recently, vaginoplasties
using cultured autologous vulvar tissue [132, 133] and
tissue-engineered biomaterial [134] have been suggested. An
alternative surgical procedure is the laparoscopic Vecchietti
vaginoplasty in which a surgical traction device is placed on
the anterior abdominal wall with subperitoneal threads at-
tached to a mold in the vagina [135, 136]. The most com-
monly used non-invasive method is self-dilation (also
referred to as Frank’s method) [137] In this method, pro-
gressive dilators are manually placed on the vaginal apex for
10–30min one to three times a day. Thorough counseling
to ensure patient readiness and firm instructions in the tech-
nique should always precede start of dilation. Therapeutical
education throughout the treatment is pivotal to achieve
success and the patient should be followed closely in order
to monitor progress and provide good support and guid-
ance. An alternative non-invasive option is dilation by inter-
course (d’Alberton’s method) [138] which has been reported
with good anatomical and functional outcome compared
with self-dilation and surgery [118, 139]. This method, how-
ever, requires regular coital activity with a partner and thus,
this approach is not an option for all patients. Importantly,
the three latter methods, which are based on dilation of the
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vaginal dimple, will provide the vagina with a normal muco-
sal lining. This may be advantageous in a uterus transplant-
ation situation (see below) since this will provide the vagina
with a normal vaginal microbiota, which may be of import-
ance for success at embryo transfer as well as for correctly
grade rejection by cervical biopsy.
A comprehensive literature review on the management
of vaginal agenesis has been conducted by Callens et al.
reviewing outcome, advantages and disadvantages of the
different procedures [140]. In general, disadvantages of the
surgical methods are the invasiveness and need of
anesthesia, the risk of neovaginal strictures requiring on-
wards dilation following surgery as well as specific compli-
cations related to different graft tissues. Disadvantages in
dilation therapy include the risk of low compliance (espe-
cially in younger patients), time consume needed for a sat-
isfactory result, the discomfort that some patients
experience, and a low risk of urethral dilation [139, 140].
Discussing different treatment options with the patient, it is
important to emphasize that there is no quick solution to
obtain a functional vagina and surgical options still require
continued postoperative dilation, by regular intercourse or
vaginal dilators, to ensure satisfactory long-term outcome.
Since 2002, The American College of Obstetricians and
Gynecologists (ACOG) has recommended dilation therapy
as first line treatment based on the high overall success rate
(90–96%), being non-invasive with a low complication rate,
and low costs [82, 141–143]. Due to the risk of low compli-
ance using dilators, the treatment should be supervised and
followed by a health professional experienced in this ther-
apy. ACOG recommends that surgery should be reserved
for patients experiencing failure with dilation therapy and
emphasizes that surgery still requires post-surgical dilation
to avoid strictures. Dilation therapy as first choice is also
supported by Callens et al. [140], which further suggest lap-
aroscopic Vecchietti vaginoplasty as preferred second-line
therapy. Most importantly, thorough counseling regarding
expected outcome and possible complications should al-
ways precede any attempt for vaginal construction, and it is
fundamental to ensure the full maturity and motivation of
the patient undergoing such treatment. Moreover, it is im-
portant to recognize the option of no treatment, which for
some patients might be the right choice [144].
Despite of the accumulated literature and the ACOG
recommendation, dilation as first-line therapy for vaginal
agenesis is still not widely accepted by surgical experts
in the field. The rarity of the syndrome implies that most
treating centers only acquire expertise and thus prefer-
ence for a single procedure. This may result in reporting
and publication biases in the available literature con-
cerning outcome and complications and it complicates
the initiation of comparative studies including both sur-
gical and non-surgical approaches. Furthermore, most
studies differ in terms of follow-up and measuring
outcome [140]. Only few comparative studies have been
reported to date [104, 118, 139, 145–150] and those
studies comparing dilation therapy with surgical proce-
dures generally conclude dilation to be non-inferior to
surgery [104, 118, 139, 145, 146, 148, 150]. Another
common limitation in most previous studies is the focus
only on anatomical outcome (neovaginal depth and
width) instead of functional outcome and patient satis-
faction [151]. Fortunately, this seems to have gained
focus in the contemporary literature. In conclusion, pro-
spective studies based on therapeutical education within
multidisciplinary expert teams using standardized out-
come measurements of both anatomical and functional
results and complications with long-term follow-up are
highly requested in order to ascertain these preliminary
reports for future clinical recommendations.
Infertility and uterus transplantation (UTx)
Women with MRKH syndrome belong to the group of
females with absolute uterine factor infertility (AUFI),
which comprise those with anatomical absence of a
uterus or presence of a non-functional uterus, in terms
of implanting an embryo and carrying a pregnancy.
Other groups of AUFI that lack a uterus, apart from
MRKH syndrome, are women hysterectomized during
fertile life because of malignancy (mainly cervical can-
cer), benign disease (leiomyoma) or as a life-saving pro-
cedure because of massive obstetrical bleeding. Women
with intrauterine adhesions, large inoperable leiomyoma,
or some specific uterine malformations also belong to
the group of women with AUFI.
The motherhood options for women with MRKH syn-
drome, and other causes of AUFI, have traditionally been
legal adoption, as international or national adoption. Since
the mid-1990s gestational surrogacy (GS), has been an al-
ternative to gain genetic motherhood, and after adoption
from the birth-giving mother, also legal motherhood. In this
procedure, in vitro fertilization is first performed with
oocytes from the MRKH woman and her partner’s sperm.
An embryo is then placed inside the womb of another
women, the gestational surrogate carrier. The GS arrange-
ment may be commercial or altruistic (typically with a close
relative (mother, sister) as the carrier) depending on juris-
diction in the specific nation/state, as exemplified by the
difference in arrangements in California, with mainly com-
mercial GS, and Canada with exclusively altruistic GS
[152]. Gestational surrogacy is not allowed in the Nordic
countries and in most other parts of the world, the reasons
being ethical, religious or legal or a combination of these
[153]. However, it is well-known that GS is used by many
women with MRKH syndrome, residing in countries with
non-approval of GS, and concerning Northern Europe the
main countries for reproductive tourism concerning GS
seem to be USA, Ukraine and Georgia. Until recently India
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was the main GS country for Nordic couples with female
AUFI, but India has now banned commercial GS [154].
Uterus transplantation (UTx) has now emerged as the
first true infertility treatment for women with MRKH
syndrome and giving them full (gestational, genetic,
legal) motherhood from start. The group in Gothenburg,
Sweden, initiated basic UTx research in animal models
already in 1999. The idea to this concept, was given by a
young woman, with cervical cancer, who would undergo
a radical hysterectomy [155]. Through structured
animal-based research [156] and continuous ethics dis-
cussions [157] within the research group in Sweden the
team optimized the surgical technique, immunosuppres-
sion for a uterine graft, rejection diagnosis as well as as-
suring normal development of the offspring from
allogeneic UTx [158]. In 2012, the team received permis-
sion from the ethics board as well as permission from
the hospital board to perform a prospective observa-
tional study of live donor UTx, including up to ten pro-
cedures. The surgeries, performed in 2013, included
eight MRKH syndrome patients and one cervical cancer
patient as recipients. The donors were five mothers, one
sister, one maternal aunt, one mother-in-law and one
family friend [159]. The surgical outcome of the nine
UTx procedures was that donor surgery was extremely
difficult, with surgical durations of 10–13 h, but that the
transplantation procedures in the recipients were sim-
pler, with surgical durations of 4–5 h. Seven out of nine
procedures were surgically successful, with viable grafts
showing regular menstruations during the first post-
transplantation year. Two out of the seven grafts had to
be surgically removed during the initial months, because
of vascular thrombosis in one case and intrauterine in-
fection in the other case [159].
The proof-of-concept of UTx as an infertility treat-
ment to women with MRKH came with the world’s first
livebirth after UTx which took place in September, 2014
in Gothenburg, Sweden [160]. Patient number 5, in the
cohort of nine women in the original Swedish UTx study
[159], had MRKH syndrome with also unilateral kidney
agenesis. She had acquired a neovagina through self-
dilation and underwent UTx at age 35 years, receiving a
uterine graft from a 61 year-old, 2-parous, family friend
that had been postmenopausal for 7 years before uterus
donation. One year after UTx she underwent transfer
with a single embryo and achieved pregnancy, which
continued essentially uneventful until the recipient ac-
quired preeclampsia in gestational week 31 + 5, with
cesarean section performed the following day. A healthy
boy was delivered and his development since then has
been normal.
This birth was followed by seven more live births in
Sweden [161, 162], until the ninth UTx baby in the
world was born in USA in December 2017, after a live
donor UTx procedure [163]. There also exist several
births after deceased donor UTx [164]. Today, approxi-
mately 75 UTx procedures have been performed and all
but two of these have been performed in MRKH patients
(Brännström, personal communication). Around 25 ba-
bies have been born worldwide, with some of the MRKH
patients having delivered healthy babies twice.
The UTx surgery of the MRKH women (Fig. 2) is gen-
erally preformed through a sub-umbilical midline inci-
sion. The vaginal vault is dissected free from the bladder
and the rectum and this is possible through cleavage of
the uterine remnant in the midline. The external iliac ar-
teries and veins are then dissected free and cleaned from
surrounding tissue, to allow for anastomosis. Bränn-
ström and his team usually also attach fixation sutures
to the sacrouterine ligaments, round ligaments and to
the cardinal ligaments. The chilled and flushed uterus is
then coming from the back-table into the pelvis. End-to-
side anastomoses are then performed with the internal
iliac segments on the uterine vessels of the graft to the
external iliac vessels of the recipient. After reperfusion,
the vagina is opened to perform end-to-end vaginal
anastomosis, which then is followed by fixation of the
uterus to the ligaments.
The immunosuppression used for the transplanted pa-
tients is standard induction therapy, similar to what is
used for kidney transplantation. The mainstay of main-
tenance immunosuppression has been the calcineurin
inhibitor, tacrolimus [162].
In the future it is likely that minimal invasive surgery,
by robotic-assisted laparoscopy, will be the main surgical
approach for live donor surgery and some years later
also for recipient surgery in UTx [165]. Advantages for
the patients will be less tissue trauma, with possibility to
Fig. 2 A transplanted uterus in the pelvis of a woman with MRKH
syndrome. The uterus is seen in the middle. The bladder is seen
below the uterus and the rectum is above
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decrease the length of hospital stay to 1–2 days and sick-
leave to 1–2 weeks.
It is important to point out that already at this early
stage of human UTx, which is still at an experimental
phase, the procedure has proved to be an effective fertil-
ity treatment with a take-home-baby rate above 80%, in
patients with graft survival of more than six months
after UTx (our unpublished observations). It is likely that
the efficiency of UTx will become even greater in the fu-
ture, in line with the advancement of other medical pro-
cedures. Another essential aspect of UTx, in comparison
to other types of solid organ transplants, is that UTx is
the first ephemeral transplantation, where immunosup-
pression is only for a restricted time, and the medication
can be withdrawn when the graft is removed. This is
typically accomplished within 5 years, when the trans-
planted woman has given birth to the desired number of
children. Thus, the negative, long-term side effects of
calcineurin inhibitors, such as nephrotoxicity, can be
avoided. This is important in the context of MRKH syn-
drome, where several patients have single kidneys.
Conclusions
The caring of patients with MRKH syndrome is complex
and requires a patient-centered multidisciplinary ap-
proach in careful dialogue with the patient addressing
all-together gynecological, sexual, psychological and in-
fertility issues. Continuous research efforts and collabo-
rations are pivotal in order to expand the current
knowledge and improve future care. Fortunately, several
advances are made these years across disciplines includ-
ing the genetics of MRKH syndrome providing a better
understanding of the etiology, improved diagnostics as
well as optimal care and counselling. Ultimately, the ad-
vent of UTx as the first available fertility treatment for
MRKH syndrome has provided new hope for these pa-
tients to become pregnant and achieve biological
motherhood.
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